CA-INSPUR-INFORMATION
23.3.2022 09:11:08 CET | Business Wire | Press release
Inspur Information, a leading IT infrastructure provider, launched the new A6 server line that supports 3rd Gen AMD® EPYCTM Milan/Milan-X 7003 series processors. The A6 server line features multi-core capabilities that show outstanding performance leaps compared to previous generation of servers with an up to 28% performance increase in SPEC performance test. The A6 server line will serve as the foundation for compute-intensive applications in the enterprise scenarios, such as big data, multi-cloud and other high-demand computing applications.
“By launching the brand new A6 servers, Inspur aims to deliver better compute performance for reliable and efficient business support. The Inspur A6 server series features best-in-class performance, energy efficiency and scalability to address the enormous computing challenges imposed by the era of big data and digital transformation”, said Ricky Zhao, Deputy General Manager of Server Product Line and General Manager of Datacenter Product Line, Inspur Information.
“AMD has been collaborating with Inspur to deliver innovative and high-performance products to the market”, said Roger Benson, Senior Director of AMD. “The new A6 server line powered by AMD EPYCTM Milan/Milan-X 7003 series processors represents the latest achievement by AMD and Inspur. With multi-core configurations and a series of performance optimizations, this server solution will unleash more possibilities for handling complex and compute-intensive workloads.”
A6 servers showcase outstanding performance with multiple cores with a high-base frequency, providing industry-leading single core capabilities. Storage density and IOPS (input/output operations per second) are increased by more than threefold. With the precision engineering and multi-level security mechanisms, A6 servers are more intelligent, easy-to-use and safer. They ensure efficient and care-free operation. It is designed with open computing standards, such as the ORS6000E rack.
A6 servers are designed to provide ultimate performance
NF3180A6/ NF3280A6 is a 1U/2U 1S rack server based on 3rd Gen AMD® EPYCTM Milan processors. Powered by multiple cores with a high-base frequency, it can serve as a high-density and cost-effective rack server that delivers strong computing power comparable to traditional dual-socket servers. With the addition of flexible expansion, it can fulfill the specific requirements for cloud computing, distributed storage, big data, CDN, video transcoding, in-memory database and virtualization scenarios.
Inspur NF5180A6/NF5280A6, powered by 3rd Gen AMD® EPYCTM processors, is a high-density dual-socket server that offers strong computing performance, ecological compatibility and configuration flexibility. This server features high quality and strong reliability, which makes it the ideal choice for a variety of complicated workloads, especially data processing, virtualization, high performance and cloud computing.
Inspur i24A6 is a 2U4N multi-node server adopting AMD EPYC™ 7002/7003 processors. It has 24 storage drives, multiple network options, and 8x 3200 MHz RDIMM/LRDIMM. It is tailored for high-performance computing and hyper-scale, and other tasks that require high core counts, large storage capacity and flexible I/O solutions.
Inheriting the design DNA of Inspur Information’s renowned server products, the A6 server line represents industry-leading performance, design and security. The line will serve as an engine to promote industrial AI and digital transformation by offering a foundation for a variety of key scenarios including multi-cloud, high-performance computing and edge computing.
About Inspur Information
Inspur Information is a leading provider of data center infrastructure, cloud computing, and AI solutions. It is the world’s 2nd largest server manufacturer. Through engineering and innovation, Inspur Information delivers cutting-edge computing hardware design and extensive product offerings to address important technology sectors such as open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, visit https://www.inspursystems.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom